PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2013-01-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 264
- Registration Number
- NCT00147498
- Locations
- πͺπΈ
Pfizer Investigational Site, Sevilla, Spain
MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 79
- Registration Number
- NCT00147550
- Locations
- πΊπΈ
Pfizer Investigational Site, Cleveland, Ohio, United States
Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4732
- Registration Number
- NCT00147602
- Locations
- π»πͺ
Pfizer Investigational Site, Caracas, Venezuela
Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HT
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2008-04-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT00147563
- Locations
- π¨π¦
Pfizer Investigational Site, Montreal, Quebec, Canada
A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2008-08-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT00147485
- Locations
- πΊπΈ
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
Time To Efficacy and Onset Of Action Of Linezolid
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 118
- Registration Number
- NCT00147511
IGF1 Generation Test
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2007-06-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 82
- Registration Number
- NCT00145457
- Locations
- π«π·
Pfizer Investigational Site, Toulouse Cedex 9, France
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 41
- Registration Number
- NCT00145431
- Locations
- π¨π¦
Pfizer Investigational Site, Quebec, Canada
Study of [S,S]-Reboxetine in Patients With Postherpetic Neuralgia, Who Are Gabapentin Treatment Failures
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2006-08-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 184
- Registration Number
- NCT00143442
A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 375
- Registration Number
- NCT00143299
- Locations
- π¦πΊ
Pfizer Investigational Site, Woodville South, South Australia, Australia
Β© Copyright 2024. All Rights Reserved by MedPath